NO143887B - Innretning for detektering av kroppsutflod, saerlig utidig urinering. - Google Patents
Innretning for detektering av kroppsutflod, saerlig utidig urinering. Download PDFInfo
- Publication number
- NO143887B NO143887B NO781672A NO781672A NO143887B NO 143887 B NO143887 B NO 143887B NO 781672 A NO781672 A NO 781672A NO 781672 A NO781672 A NO 781672A NO 143887 B NO143887 B NO 143887B
- Authority
- NO
- Norway
- Prior art keywords
- pyrazole
- hydroxy
- androstene
- urination
- flow detection
- Prior art date
Links
- 238000001514 detection method Methods 0.000 title 1
- 230000027939 micturition Effects 0.000 title 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 150000001340 alkali metals Chemical class 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000006193 liquid solution Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 9
- 239000013078 crystal Substances 0.000 description 7
- RLCPFNGRZDFWIW-UHFFFAOYSA-N 2-[[4-(4-pyridazin-4-yl-1h-pyrazol-5-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1C=1NN=CC=1C1=CC=NN=C1 RLCPFNGRZDFWIW-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IATKKATWPOVYCC-VMXHOPILSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CC2=CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 IATKKATWPOVYCC-VMXHOPILSA-N 0.000 description 1
- -1 3-hydroxy-17a-methylandrostane Chemical compound 0.000 description 1
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229910000906 Bronze Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000010974 bronze Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- DFOXKPDFWGNLJU-UHFFFAOYSA-N pinacolyl alcohol Chemical compound CC(O)C(C)(C)C DFOXKPDFWGNLJU-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/48—Devices for preventing wetting or pollution of the bed
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Environmental & Geological Engineering (AREA)
- Nursing (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Electrotherapy Devices (AREA)
Description
Fremgangsmåte for fremstilling av 17p-hydroksy-androstan (3,2-c)pyrazol eller et 17p-hydroksy-17a-lavere-alkyl-androstan (3,2-c)-pyrazol.
Denne oppfinnelse angår en fremgangsmåte for fremstilling av 17|3-hydrok-syandrostan[3.2-c]pyrazol eller et 17(3-hydroksy-17ct-lavere-alkylandrostan-[3.2-c]pyrazol ved reduksjon av de tilsva-rende 4-androsten [3,2-c] pyrozoler.
De forbindelser som fåes ved denne
fremgangsmåte, altså androstan[3.2-c]py-razoler, utgjør verdifulle anaboliske mid-ler. Disse forbindelser, samt utgangsmate-rialene for fremgangsmåten, er beskrevet i
belgisk patent nr. 577 027, som ble bevilget
den 24.9.1959.
Man har funnet at 17|3-hydroksy-4-androsten[3.2-c]pyrazol og 17a-lavere-al-kylderivater av denne kan reduseres til
17(3-hydroksy-androstan[3.2-c]pyrazol og
til 17a-lavere-alkyl-derivater av denne, ved
at førstnevnte behandles med en flytende
ammoniakkoppløsning av et alkalimetall
(litium, natrium, kalium, rubidium eller
cesium) eller av et jordalkalimetall (kalsi-um, strontium eller barium), og med en
lavere alkanol. Overraskende viste det seg
at dobbeltbindingen ble redusert med ut-merket utbytte uten innvirkning på pyr-azolringsystemet og uten at det ble dan-net vesentlige mengder av den 5(3-isomere
(ringer A/Bcis).
Den omdannelse som foregår ved fremgangsmåten i henhold til oppfinnelsen be-lyses ved de følgende strukturformler:
I de ovenfor nevnte formler betegner R et hydrogenatom eller et laverealkyl-radi-kal, som inneholder fra 1 til ca. 4 karbon-atomer, deriblant metyl, etyl, propyl, iso-propyl, butyl, isobutyl og lignende.
Reaksjonsmediet kan inneholde et inert oppløsningsmiddel, f. eks. et flytende hydrokarbon eller en alifatisk eller cyklo-alifatisk eter som tjener som oppløsnings-middel for steroidet og som fortynnings-middel for den flytende ammoniakk. Et foretrukket inert oppløsningsmiddel er tetrahydrofuran.
For å sikre at reaksjonen fullføres, kreves det minst 4 gramatomer alkalimetall (2 gramatom jordalkalimetall) pr. mol steroid. Det foretrekkes å anvende et stort overskudd av metallet.
Den lavere alkanol blir fortrinnsvis tilsatt etter at steroidet og metallet er blitt løst opp i den flytende ammoniakk. Det kan anvendes en hvilken som helst lavere alkanol som inneholder fra 1 til ca. 6 kar-bonatomer, f. eks. metanol, etanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, tert.-butyletanol, amylalkohol, heksylal-kohol og lignende.
Mengdeforholdene av flytende ammoniakk, inert oppløsningsmiddel og lavere alkanol i forhold til mengden av steroid kan variere innenfor vide grenser. De føl-gende eksempler belyser oppfinnelsen uten å angi grenser for denne.
Eksempel 1.
Til en omrørt oppløsning av 1,00 g 17(3-hydroksy- 17a-metyl-4-androsten-[3.2-c]pyrazol i 200 ml tetrahydrofuran og 400 ml flytende ammoniakk ble det i løpet av 5 minutter tilsatt 2,12 g litium i tråd-form. Den mørkeblå oppløsning ble omrørt i 45 minutter. Deretter ble det under om-røring tilsatt en oppløsning av 40 ml terti-ær butylalkohol i 160 ml dietyleter. Etter 15 minutters forløp ble 25 ml etanol tilsatt under omrøring. Blandingen ble fargeløs etter flere timers forløp, og den flytende ammoniakk fikk fordampe og blandingen fikk oppvarme seg til romtemperatur i lø-pet av ca. 15 timer. Oppløsningsmidlet ble fordampet, hvorved det ble tilbake en far-geløs, fast rest, som ble tatt opp i en blan-ding av etylacetat og isvann. De to lag ble skilt fra hverandre og det vandige lag ble ekstrahert med etylacetat. De forente orga-niske lag ble vasket med vann, mettet med natriumkloridoppløsning og filtrert gjennom vannfritt natriumsulfat. Oppløsnings-midlet ble fordampet og man fikk 1,20 g av svakt lysebrune krystaller med smeltepunkt 151—155°C og ultrafiolett maksimum ved 224 m|.i (E = 4,095). Ved to omkrystallisasjoner fra etanol fikk man et første utbytte på 0,619 g (62 pst.) av fargeløse krystaller med smeltepunkt 232,8—238,0°C. Ultrafiolett maksimum ved 224 m^ (E = 4.840), [a] <2>D<5> (1 pst. i CHC13) = +34,8°C, samt et neste utbytte på 0,142 g farge-løse krystaller med sm.p. 234—242°C. Blan-dings-smeltepunktet med autentisk 17(3-hydroksy-17a-metylandrostan [3.2-c ] pyrazol, fremstilt som i det foran nevnte patent, var 228—241 °C. De infrarøde spektra var identiske.
Eksempel 2.
il en omrørt oppløsning av 10,0 g 17|3-hydroksy-17a-metyl-4-androsten[3.2-c]-
pyrazol i 300 ml tetrahydrofuran og 300 ml flytende ammoniakk, i en 2-liters, trehalset kolbe med rund bunn, som var utstyrt med et natronkalk-tørkerør og med et mekanisk Hershberg-røreverk, ble det i løpet av 5 minutter tilsatt 20 g natrium. Det ble dan-net et øvre, bronsefarget lag og et nedre grått ugjennomsiktig lag. Blandingen ble omrørt i 1 time, hvoretter det under om-røring ble tilført 100 ml etanol gjennom en trykkutj evnet dryppetrakt, i løpet av
15 minutter. Blandingen ble opphetet med
tilbakeløpskjøling i ytterligere 6 timer (de
to lag forefantes fremdeles på dette tids-punkt), hvoretter ammoniakken fikk fordampe og blandingen fikk anta romtemperatur i løpet av ca. 15 timer. Den grå blan-ding, som inneholdt både fast stoff og væs-ke, ble under nedsatt trykk inndampet til ca. 200 ml og ble deretter under omrøring helt ut i 1500 ml isvann. Blandingen ble filtrert og det oppsamlede faste stoff ble vasket med vann og deretter suget tørt
hvorved man fikk lysegule krystaller. En
del av disse ble tørket i vakuum ved 120°C i 64 timer, hvorved man fikk lysegule krystaller av smeltep. 157—165°C, som ved del-vis omkrystallisasjon hadde smeltep. <215°
C, ultrafiolett maksimum ved 223 mu, (E = 4,600), 260 m^i (E = 130) (>98 pst. reduksjon). To omkrystallisasjoner fra etanol ga 6,38 g (63 pst.) fargeløse krystaller av 17(3-hydroksy-17a-metylandrostan[3.2-c]pyrazol (tørket i vakuum ved 120°C i 20 timer), smeltep. 232—241 °C, ultrafiolett maksimum ved 223 mp, (E = 4,710), [a]<2>DS (1 pst. i CHCl.j) - +34,9°C. Fra moderlutene ble det erholdt følgende utbytter etter be-handling med aktivert kull og mange omkrystallisasjoner fra etanol: 1,18 g lysegule krystaller (tørket i vakuum i 17 timer), sm.p. 224—245°C, ultrafiolett maksimum ved 223 (E = 4,650), 260 m^ (E = 96), [a]25 (1 pst. i CHC13) = +34,8°C; 0,37 g, sm.p. 153—157°C, atter stivnet, sm.p. 222— 230°C; 0,10 g, sm.p. 151—154°C, atter stivnet, sm.p. 227—243°C; 0,47 g sm.p. 207— 242°C.
Ved å anvende den ovennevnte fremgangsmåte ble 17(3-hydroksy-4-androsten-[3.2-c]pyrazol, 17|3-hydroksy-17a-etyl-4-androsten[3.2-c]pyrazol, 17|3-hydroksy-17a-propyl-4-androsten[3.2-c]pyrazol, 17(3-hydroksy-17a-isopropyl-4-androsten-[3.2-c]pyrazol eller 17|3-hydroksy-17a-butyl-4-androsten[3.2-c]pyrazol redusert til 17(3-hydroksyandrostan[3.2-c]pyrazol, 17(3-hydroksy-17a-etylandrostan[3,2-c]pyrazol, 17(3-hydroksy-17a-propylandrostan-[3.2-c]pyrazol, 17|3-hydroksy-17ct-isopro-pyl-androstan[3.2-c]pyrazol, eller 17(3-hydroksy-17<x-butylandrostan[3.2-c]pyrazol.
Claims (2)
1. Fremgangsmåte for fremstilling av 17|3-hydroksy-androstan[3.2-c]pyrazol eller
et 170-hydroksy- 17a-laverealkyl-androstan[3.2-c]pyrazol, karakterisert ved at man behandler 17[3-hydroksy-4-andro- sten[3.2-c]pyrazol eller et 17(3-hydroksy-
17a-laverealkyl-4-androsten[3.2-c]pyrazol med en flytende oppløsning i ammoniakk av et alkalimetall eller et jordalkalimetall, og med en lavere alkanol, fortrinnsvis etanol.
2. Fremgangsmåte ifølge påstand 1, karakterisert ved at alkalimetallet er litium eller natrium.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB20486/77A GB1603856A (en) | 1977-05-16 | 1977-05-16 | Arrangement for detecting and controlling an outflow from living bodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO781672L NO781672L (no) | 1978-11-17 |
| NO143887B true NO143887B (no) | 1981-01-26 |
| NO143887C NO143887C (no) | 1981-05-06 |
Family
ID=10146698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO781672A NO143887C (no) | 1977-05-16 | 1978-05-11 | Innretning for detektering av kroppsutflod, saerlig utidig urinering. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4205671A (no) |
| AT (1) | ATA343678A (no) |
| BE (1) | BE866984A (no) |
| BR (1) | BR7803054A (no) |
| DE (1) | DE2820565A1 (no) |
| DK (1) | DK204278A (no) |
| FI (1) | FI66118C (no) |
| FR (1) | FR2390941A1 (no) |
| GB (1) | GB1603856A (no) |
| NL (1) | NL7805207A (no) |
| NO (1) | NO143887C (no) |
| SE (1) | SE433803B (no) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4738260A (en) * | 1985-04-18 | 1988-04-19 | Travis Industries, Inc. | Unintentional urination sensing device |
| US4800370A (en) * | 1985-10-07 | 1989-01-24 | I E Sensors, Inc. | Wetness detection system |
| US4706071A (en) * | 1986-04-16 | 1987-11-10 | Lin Min Shin | Warning apparatus against the coverlet out of position |
| GB2192323B (en) * | 1986-07-11 | 1990-07-25 | Stewart Matthew Womar | Urination deterrent device |
| US5036859A (en) * | 1988-07-26 | 1991-08-06 | Travis International, Inc. | Moisture detector and indicator |
| US4977906A (en) * | 1989-03-07 | 1990-12-18 | Scipio William J Di | Diurnal rehabilitation for incontinence trainer |
| DE3921784A1 (de) * | 1989-07-01 | 1991-01-10 | Rolf Ehlers | Ambulantes geraet zur koerpernahen ueberwachung und beeinflussung unbewusster lebensfunktionen |
| KR940003280B1 (ko) * | 1991-10-24 | 1994-04-20 | 손종은 | 환자의 용변 처리장치 |
| US5416469A (en) * | 1991-12-23 | 1995-05-16 | Colling; Joyce C. | Method for prediction of times of voiding utilizing temperature measurements |
| US5258745A (en) * | 1991-12-23 | 1993-11-02 | Colling Joyce C | System and method for prediction of times of voiding utilizing temperature measurements |
| US5447526A (en) * | 1992-12-24 | 1995-09-05 | Karsdon; Jeffrey | Transcutaneous electric muscle/nerve controller/feedback unit |
| US5370670A (en) * | 1993-12-13 | 1994-12-06 | Thomas Jefferson University | Detrusor myoplasty and neuromuscular electrical stimulation of the urinary bladder |
| US5559497A (en) * | 1994-11-28 | 1996-09-24 | Hong; Chia-Ping | Body temperature sensing and alarming device |
| US6325066B1 (en) * | 1996-08-26 | 2001-12-04 | Charles B. Hughes | Bladder and bowel training system with removable voice module system |
| FR2798475B1 (fr) * | 1999-09-14 | 2001-10-19 | Christophe Cayrol | Dispositif permettant d'avertir une personne se deplacant sur un chemin donne, de la presence, sur ce chemin, d'objets presentant eventuellement un danger pour elle |
| US6603403B2 (en) | 2000-12-12 | 2003-08-05 | Kimberly-Clark Worldwide, Inc. | Remote, wetness signaling system |
| US6583722B2 (en) | 2000-12-12 | 2003-06-24 | Kimberly-Clark Worldwide, Inc. | Wetness signaling device |
| US8000792B1 (en) | 2002-03-29 | 2011-08-16 | Dechev George D | Fast-acting counter-incontinence method and device |
| US6553266B1 (en) * | 2002-06-18 | 2003-04-22 | Jui-Kuang Yuang | Underpants structure provided with means to augment perineal muscles |
| US20050099294A1 (en) * | 2003-08-05 | 2005-05-12 | Bogner James T. | System for managing conditions |
| US7219627B1 (en) * | 2003-09-22 | 2007-05-22 | Electronic Materials Llc | Electrical bandage protector |
| US7737321B2 (en) * | 2003-09-23 | 2010-06-15 | Elliott Nyle S | colostomy alert device and method |
| US8109982B2 (en) * | 2005-06-23 | 2012-02-07 | Morteza Naghavi | Non-invasive modulation of the autonomic nervous system |
| US7855653B2 (en) * | 2006-04-28 | 2010-12-21 | Medtronic, Inc. | External voiding sensor system |
| US7522061B2 (en) * | 2006-04-28 | 2009-04-21 | Medtronic, Inc. | External voiding sensor system |
| FR2935906B1 (fr) * | 2008-09-16 | 2011-03-11 | I Gen Healthcare Ltd | Dispositif de reeducation perineale. |
| US9320893B2 (en) | 2011-05-06 | 2016-04-26 | Blue Medical Innovation Ltd. | Vaginal rehabilitative device |
| CN104545927B (zh) * | 2015-01-09 | 2017-02-22 | 袁久洪 | 电子智能阴茎勃起功能监测仪 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB680088A (en) * | 1950-03-31 | 1952-10-01 | Univ Adelaide | Apparatus for applying conditioning stimuli to enuretics |
| DK97424C (da) * | 1960-03-07 | 1963-11-25 | Laege Kristen Fabricius Krarup | Apparat til forhindring af utidig vandladning. |
| SU146259A1 (ru) * | 1961-05-09 | 1961-11-30 | Б.И. Ласков | Устройство дл определени истинного или ложного ночного недержани мочи |
| US3316902A (en) * | 1963-03-25 | 1967-05-02 | Tri Tech | Monitoring system for respiratory devices |
| FR2042490A1 (fr) * | 1969-05-08 | 1971-02-12 | Odin Clorius As | Debitmetre perfectionne |
| US3645133A (en) * | 1970-04-15 | 1972-02-29 | Metrophysics Inc | Electronic spirometer |
| US3942515A (en) * | 1974-09-11 | 1976-03-09 | Instrumentation & Control Systems, Inc. | Air caloric stimulation system |
| NL7503935A (en) * | 1975-04-02 | 1976-10-05 | Henriette Annie Bijkerk Van De | Enuresis bandage alarm - has liquid switch shunted by electronic switch becoming conductive when liquid switch closes |
-
1977
- 1977-05-16 GB GB20486/77A patent/GB1603856A/en not_active Expired
- 1977-09-02 US US05/830,216 patent/US4205671A/en not_active Expired - Lifetime
-
1978
- 1978-05-10 DK DK204278A patent/DK204278A/da not_active Application Discontinuation
- 1978-05-11 AT AT0343678A patent/ATA343678A/de not_active IP Right Cessation
- 1978-05-11 DE DE19782820565 patent/DE2820565A1/de not_active Withdrawn
- 1978-05-11 NO NO781672A patent/NO143887C/no unknown
- 1978-05-12 NL NL7805207A patent/NL7805207A/xx not_active Application Discontinuation
- 1978-05-12 FR FR7814270A patent/FR2390941A1/fr active Pending
- 1978-05-12 BE BE2056964A patent/BE866984A/xx not_active IP Right Cessation
- 1978-05-12 FI FI781506A patent/FI66118C/fi not_active IP Right Cessation
- 1978-05-15 BR BR7803054A patent/BR7803054A/pt unknown
- 1978-05-16 SE SE7805533A patent/SE433803B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE2820565A1 (de) | 1978-11-30 |
| FI781506A (fi) | 1978-11-17 |
| FI66118B (fi) | 1984-05-31 |
| BE866984A (nl) | 1978-09-01 |
| ATA343678A (de) | 1986-11-15 |
| NO781672L (no) | 1978-11-17 |
| DK204278A (da) | 1978-11-17 |
| FI66118C (fi) | 1984-09-10 |
| NO143887C (no) | 1981-05-06 |
| US4205671A (en) | 1980-06-03 |
| SE433803B (sv) | 1984-06-18 |
| FR2390941A1 (fr) | 1978-12-15 |
| GB1603856A (en) | 1981-12-02 |
| NL7805207A (nl) | 1978-11-20 |
| BR7803054A (pt) | 1979-01-02 |
| SE7805533L (sv) | 1978-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO143887B (no) | Innretning for detektering av kroppsutflod, saerlig utidig urinering. | |
| Barton et al. | A Synthesis of Aldosterone Acetate1 | |
| US2738350A (en) | 3-oxygenated 17alpha-aza-d-homoandrostenes and n-substituted derivatives thereof | |
| US3030358A (en) | Process for reduction of delta4 androstene [3.2-c] pyrazole compounds | |
| US4325879A (en) | Amino-14 steroid derivatives and process for preparation of the same | |
| NO128533B (no) | ||
| US2819276A (en) | 3, 19-dihydroxy-4-androsten-17-one | |
| US2702811A (en) | 19-nor-steroids | |
| US2817671A (en) | 16-cyano and 16-cyanoalkyl 3, 20-dioxy-genated pregnenes | |
| US3060174A (en) | Esters of the androstane series and process for their manufacture | |
| Strunz et al. | Fittig bislactones in cyclopentenone synthesis: short synthesis of methylenomycin B | |
| US3773758A (en) | 7alpha-cyano-17-hydroxy-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid ypsilon-lactone and related compounds | |
| SU826957A3 (ru) | Способ получения 11[ь-окси-18-метилстероидов' эстранового ряда . | |
| NO134990B (no) | ||
| US2740781A (en) | 3, 26-dihydroxy-16, 22-imino-5-cholestenes, 3, 26-dihydroxy-16, 22-imino-5, 16, 20(22)-cholestatrienes and derivatives thereof | |
| US3097200A (en) | 17-aminoandrostanes | |
| US3145200A (en) | Steroido[3.2-c]isoxazoles and preparation thereof | |
| US3574688A (en) | Unsaturated 2-oxa steroid derivatives and process for their preparation | |
| US3407219A (en) | 17alpha-alkyl-17beta-methyl-8xi, 9xi, 13xi, 14xi-gona-1,3,5(10)-trien-3-ols and conge | |
| US3507889A (en) | Process for the preparation of 17alpha-dihydroequilenin and related compounds | |
| DE2436332A1 (de) | Substituierte tetrahydrofurane und verfahren zu deren herstellung | |
| US3414566A (en) | 17-substituted-3alpha, 5-cyclo-6beta, 19-oxido-5alpha-steroids and process for preparing the same | |
| US2495735A (en) | Process for preparing lower alkyl esters of 3-hydroxy-11-keto-12-bromonorcholanic acid | |
| US3300523A (en) | 3-oxygenated 17beta-oxy-17alpha-pregnen-20-yn-21-yltri (alkyl/aryl) silanes and congeneric 3-desoxy-3, 5-dienes | |
| US2838529A (en) | 13-methyl-17-hydroxy-17-vinyl-1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17-tetradechaydro-15h-cyclopenta [a] phenanthren-3-one |